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Clinical Care Guidelines: Too Much of a
Good Thing?
C
ystic ﬁbrosis (CF) is one of the most
common life-threatening inherited
disorders in Caucasian populations,
affecting 30,000 children and adults in
the U.S. and 70,000 worldwide. Due to
advances in pulmonary care and nutri-
tion, the life expectancy for CF has in-
creased from less than 5 years in the
1950s to greater than 37 years at present,
with many patients living into their ﬁfth
and sixth decades (1).
Hyperglycemia is an increasingly rec-
ognizedextra-pulmonarycomplicationof
CF. The prevalence of CF–related diabe-
tes (CFRD) increases with age, affecting
20% of adolescents and 50% of adults by
30 years of age (2). Unfortunately, pro-
spective, controlled data regarding CFRD
are limited. Therefore, the approach to
detection, classiﬁcation, and manage-
mentofthisimportantconsequenceofCF
varies widely between centers and indi-
vidual care providers.
To address this deﬁciency, and in an
attempt to provide more uniform stan-
dards of care for patients with CFRD, a
committeeofCFanddiabetesexpertsmet
in2009todevelopclinicalcareguidelines
for CFRD. The results of their collabora-
tion are published in this issue of Diabetes
Care, accompanied by a technical review
that summarizes the epidemiology,
pathophysiology, and prognostic impli-
cations of CFRD (3,4).
The updated guidelines are based on
an extensive review of the available evi-
dence and are important for a number of
reasons. They highlight the spectrum of
glucoseintoleranceinCFpatientsandthe
ways in which CFRD is a distinct clinical
entity from other types of diabetes. For
example,therecommendationagainstus-
ing A1C as a screening tool for CFRD and
the recommendation to maintain high ca-
loric intake are critical differences from
the care of non-CF diabetic patients. We
areremindedthatprandialglucoseexcur-
sions(andthusprandialinsulinneeds)far
outweighfastingbloodglucoseelevations
untillaterinthecourseofCFRD,andthat
insulin needs exponentially increase dur-
ing acute illness (and, conversely, rapidly
drop during recovery). Recognition of
theseuniqueaspectsofCFRDisnecessary
to optimize the care of patients with
CFRD and to prevent inadvertent harm.
The guidelines process always neces-
sitates extrapolating from a variety of ev-
idence sources of variable quality and
generally of modest scope. As a result,
usually the guidance can be characterized
as well-intentioned, informed guessing.
Inthebestofcircumstances,theguideline
will result in codifying practices with
clear beneﬁt, eliminating practices with
clear harm, and avoiding recommenda-
tions where data are insufﬁcient.
InthecaseoftheCFRDguidelines,24
of the 30 recommendations are graded as
Level E under the American Diabetes As-
sociation(ADA)classiﬁcationsystem,i.e.,
based on consensus or expert opinion.
Notably, the four recommendations
gradedasLevelB(LevelBorDunderU.S.
Preventive Services Task Force [USPSTF]
classiﬁcation, depending on whether the
data are for or against the recommenda-
tion) relate to screening (avoiding A1C,
commencing at 10 years of age), classiﬁ-
cation (not distinguishing between CF
with and without fasting hyperglycemia),
and A1C goals (7% in most patients with
CFRD). The recommendations to use in-
sulinfortreatingCFRDandtoavoidusing
oral agents except in research settings are
the sole guidelines graded as Level A
(Levels B and D, respectively, by USPSTF
schema).
The remaining guidance is based on
increasing knowledge about the preva-
lence of CFRD and its negative impact on
nutritional status, pulmonary function,
and mortality. It is clear that an inverse
association exists between hyperglycemia
and BMI, lung function, and survival (5–
9). However, the causal nature of this re-
lationship is not clear. There are several
hypotheses to explain this relationship,
one being that insulin deﬁciency in pa-
tients with CF leads to the loss of calories
and muscle mass, ultimately causing de-
cline in pulmonary status and earlier
death. Multiple studies have demon-
stratedthatinsulintherapyinCFRDcan
improve the above-mentioned out-
comes,butonlyoneofthesestudieswas
a randomized controlled trial (10).
Thus, it must also be considered that
the association between insulin deﬁcien-
cy/hyperglycemia and negative CF out-
comes might not be causative, but rather
due to other potential mechanisms such
asthepresenceofmoreadvancedpancre-
atic endocrine dysfunction in the sickest
patients.
This concern about causality is not
unique to CFRD. It has featured promi-
nently in discussions about inpatient gly-
cemic control as well as aggressive
outpatientcontrolaimedatloweringA1C
below 7.0%. With respect to inpatient
glycemic control, epidemiologic data
consistently linked inpatient hyperglyce-
mia to poor outcomes. Several large
controlled trials showed marked im-
provements in morbidity and mortality
with aggressive control of blood glucose
inintensivecareunitpatients(11,12),but
subsequent studies did not conﬁrm the
beneﬁt in broader inpatient populations
(13).Similarly,becauseastrongepidemi-
ologic association exists between even
modest levels of hyperglycemia and mac-
rovascular disease in the outpatient pop-
ulation, multiple large-scale trials were
undertaken to prove the cardiovascular
and mortality beneﬁts of treating diabet-
ics to near-normal A1C (14–16); the re-
sult was no beneﬁt in most cases and
perhaps harm (14). The evidence base
that epidemiology and “physiologic
thinking” do not always translate to clin-
ical beneﬁts grows month by month.
What are the potential harms of these
guidelines, which rely heavily on expert
opinion as a result of a generally weak
evidence base? One danger is that pa-
tients, care providers, and institutions, all
eager for action to address the growing
problem of hyperglycemia in patients
with CF, will implement the universal
screening and early insulin treatment
without adequate safety measures. The
guidelines suggest that hypoglycemia is
notassevereorasfrequentinCFRDcom-
pared with other forms of diabetes. While
neuroglycopenic symptoms and life-
threatening hypoglycemia might be less
common in CFRD, symptomatic hypo-
glycemia with a robust adrenergic re-
sponse occurs quite frequently. This is a
frightening experience for patients, and
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creasewithtreatmentofmilderdegreesof
hyperglycemia. In the inpatient setting,
more aggressive treatment must be ac-
companied by appropriate education and
follow-up to facilitate rapid decreases in
insulin doses with recovery and particu-
larly with continued clinical improve-
ment at home.
Patients who have negative experi-
ences with insulin therapy may be less
willing to adhere to multiple daily insulin
injections and frequent blood glucose
monitoring, both of which become
essential later in life as their diabetes
progresses. Patients with CF and their
families already struggle with the burden
ofachronic,life-threateningillness;more
intensive effort and attention to diabetes
will increase that burden, perhaps to the
detriment of other health care behaviors
for which the evidence base for beneﬁt is
greater. Hospitals and CF programs will
invest more time, money, and personnel
to implement these more intensive diabe-
tes treatment protocols, which may or
may not achieve the intended goals but
certainly will inhibit other initiatives. A
ﬁnalconcern,withthefurthestreaching
implications, is that these guidelines
could create issues regarding what
“standard of care” ethically can be used
in the comparison group in future stud-
ies of intensive management of CFRD.
Speciﬁcally, these guidelines are not
based on long-term, large-scale trials
with end points important to patients
such as quality of life, disability, or
death. But future institutional ethical
review boards could hold investigators
accountable for providing care in line
with these guidelines, inhibiting much-
needed research to actually demon-
strate that these guidelines are effective
in improving quality of life, functional
status, and survival.
This is not to say we should avoid
embracing these CFRD guidelines for fear
of treatment side-effects or concern about
the complexity of implementation. On
the contrary, we know that CFRD devel-
ops in most patients with CF over time
and,therefore,itshouldberegardedasan
integral aspect of CF care rather than as a
separate disease entity. We know that mi-
crovascular complications occur in a sig-
niﬁcant number of patients with CFRD,
so screening for and treating eye, kidney,
and neurologic diseases are imperative.
We know that CFRD is different in many
waysfromtype1andtype2diabetes,and
thus all members of the CF team should
be educated about the unique aspects in-
volved in caring for these patients. CF
programs should establish review pro-
cesseswithmeasurementspriortoandaf-
ter interventions and a comprehensive
CFRD care team consisting of representa-
tives from pulmonary, endocrine, nutri-
tion, and diabetes education. At the
University of North Carolina School of
Medicine, we have developed a CFRD
quality improvement initiative with the
establishment of a CFRD database, goal
setting,andmonthlyreviewsofoutcomes
and next steps.
Our hope is that the clinical care
guidelines for CFRD will be utilized as
they were intended: to guide us in an area
of certain import but uncertain evidence.
Thequestionstheyhavegeneratedshould
serve as the basis for future research,
which is critical to identifying adverse
outcomes caused by insulin deﬁciency/
hyperglycemia and the interventions that
will attenuate these risks.
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